AMIX
Autonomix Medical, Inc.
Price Chart
Latest Quote
$0.40
Current Price| Previous Close | $0.40 |
| Open | $0.40 |
| Day High | $0.42 |
| Day Low | $0.38 |
| Volume | 183,186 |
Stock Information
| Shares Outstanding | 6.91M |
| Cash Equivalents | $7.48M |
| Net Income | $-16.69M |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | $2.80M |
| EPS (TTM) | $-4.51 |
| Exchange | NCM |
đ Custom Metrics & Score
Score: 19/42| Debt to Equity | 0.21 |
| Debt to Earnings | -0.15 |
| Current Ratio | 5.63 |
| Quick Ratio | 5.35 |
| Return on Equity | -140.88% |
| Avg FCF Growth | 115.39% |
| FCF Yield | -295.83% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $0.41 | 183,200 |
| 2026-01-30 | $0.40 | 224,700 |
| 2026-01-29 | $0.40 | 379,000 |
| 2026-01-28 | $0.42 | 193,700 |
| 2026-01-27 | $0.42 | 227,500 |
| 2026-01-26 | $0.43 | 301,300 |
| 2026-01-23 | $0.47 | 362,300 |
| 2026-01-22 | $0.47 | 384,300 |
| 2026-01-21 | $0.45 | 351,400 |
| 2026-01-20 | $0.47 | 490,400 |
| 2026-01-16 | $0.47 | 609,300 |
| 2026-01-15 | $0.52 | 357,300 |
| 2026-01-14 | $0.53 | 563,700 |
| 2026-01-13 | $0.50 | 886,000 |
| 2026-01-12 | $0.50 | 1,723,100 |
| 2026-01-09 | $0.51 | 43,106,200 |
| 2026-01-08 | $0.50 | 385,400 |
| 2026-01-07 | $0.49 | 770,000 |
| 2026-01-06 | $0.51 | 882,000 |
| 2026-01-05 | $0.54 | 852,400 |
About Autonomix Medical, Inc.
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company's technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Medical, Inc. was incorporated in 2014 and is headquartered in The Woodlands, Texas.
Income Statement (Annual)
Revenue
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|
| Total Revenue | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 |
Expenses
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|
| Interest Expense | $176,000 | $79,000 | $0 |
| Total Expenses | $11,588,000 | $7,474,000 | $1,990,000 |
| Net Non Operating Interest Income Expense | $178,000 | $48,000 | $0 |
| Interest Expense Non Operating | $176,000 | $79,000 | $0 |
| Operating Expense | $11,588,000 | $7,474,000 | $1,990,000 |
| General And Administrative Expense | $6,863,000 | $5,249,000 | $1,245,000 |
| Other Income Expense | - | $-8,000,000 | - |
Income & Earnings
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-11,410,000 | $-15,426,000 | $-1,990,000 |
| Net Interest Income | $178,000 | $48,000 | $0 |
| Interest Income | $354,000 | $127,000 | $0 |
| Normalized Income | $-11,410,000 | $-7,426,000 | $-1,990,000 |
| Net Income From Continuing And Discontinued Operation | $-11,410,000 | $-15,426,000 | $-1,990,000 |
| Total Operating Income As Reported | $-11,588,000 | $-12,030,000 | $-1,990,000 |
| Net Income Common Stockholders | $-11,410,000 | $-15,426,000 | $-1,990,000 |
| Net Income | $-11,410,000 | $-15,426,000 | $-1,990,000 |
| Net Income Including Noncontrolling Interests | $-11,410,000 | $-15,426,000 | $-1,990,000 |
| Net Income Continuous Operations | $-11,410,000 | $-15,426,000 | $-1,990,000 |
| Pretax Income | $-11,410,000 | $-15,426,000 | $-1,990,000 |
| Interest Income Non Operating | $354,000 | $127,000 | $0 |
| Operating Income | $-11,588,000 | $-7,474,000 | $-1,990,000 |
Per Share Metrics
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|
| Diluted EPS | $-6.46 | $-14.82 | $-1.88 |
| Basic EPS | $-6.46 | $-14.82 | $-1.88 |
Other
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-11,051,000 | $-7,266,000 | $-1,990,000 |
| Reconciled Depreciation | $183,000 | $81,000 | $0 |
| EBITDA (Bullshit earnings) | $-11,051,000 | $-15,266,000 | $-1,990,000 |
| EBIT | $-11,234,000 | $-15,347,000 | $-1,990,000 |
| Diluted Average Shares | $1,766,425 | $1,040,720 | $1,055,891 |
| Basic Average Shares | $1,766,425 | $1,040,720 | $1,055,891 |
| Diluted NI Availto Com Stockholders | $-11,410,000 | $-15,426,000 | $-1,990,000 |
| Tax Provision | $0 | $0 | $0 |
| Research And Development | $4,725,000 | $2,225,000 | $745,000 |
| Selling General And Administration | $6,863,000 | $5,249,000 | $1,245,000 |
| Other Gand A | $6,863,000 | $5,249,000 | $1,245,000 |
| Total Unusual Items | - | $-8,000,000 | - |
| Total Unusual Items Excluding Goodwill | - | $-8,000,000 | - |
| Gain On Sale Of Security | - | $-8,000,000 | - |
Balance Sheet (Annual)
Assets
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|
| Net Tangible Assets | $8,099,000 | $7,628,000 | $644,000 |
| Total Assets | $9,806,000 | $9,407,000 | $865,000 |
| Total Non Current Assets | $197,000 | $16,000 | $0 |
| Non Current Deferred Assets | $176,000 | $0 | - |
| Current Assets | $9,609,000 | $9,391,000 | $865,000 |
| Other Current Assets | $473,000 | $783,000 | - |
| Cash Cash Equivalents And Short Term Investments | $9,136,000 | $8,608,000 | $865,000 |
| Cash And Cash Equivalents | $9,136,000 | $8,608,000 | $865,000 |
| Cash Financial | - | $8,608,000 | $865,000 |
Debt
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|
| Total Debt | - | $1,002,000 | - |
| Long Term Debt And Capital Lease Obligation | - | $1,002,000 | - |
| Long Term Debt | - | $1,002,000 | - |
Liabilities
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|
| Total Liabilities Net Minority Interest | $1,707,000 | $1,779,000 | $221,000 |
| Total Non Current Liabilities Net Minority Interest | $0 | $1,002,000 | $0 |
| Current Liabilities | $1,707,000 | $777,000 | $221,000 |
| Payables And Accrued Expenses | $1,707,000 | $777,000 | $221,000 |
| Payables | $676,000 | $492,000 | $173,000 |
| Accounts Payable | $676,000 | $492,000 | $173,000 |
Equity
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|
| Common Stock Equity | $8,099,000 | $7,628,000 | $644,000 |
| Total Equity Gross Minority Interest | $8,099,000 | $7,628,000 | $644,000 |
| Stockholders Equity | $8,099,000 | $7,628,000 | $644,000 |
| Retained Earnings | $-50,379,000 | $-38,969,000 | $-23,543,000 |
Other
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|
| Ordinary Shares Number | $2,497,033 | $942,304 | $1,055,891 |
| Share Issued | $2,497,033 | $942,304 | $1,055,891 |
| Tangible Book Value | $8,099,000 | $7,628,000 | $644,000 |
| Invested Capital | $8,099,000 | $8,630,000 | $644,000 |
| Working Capital | $7,902,000 | $8,614,000 | $644,000 |
| Total Capitalization | $8,099,000 | $8,630,000 | $644,000 |
| Additional Paid In Capital | $58,476,000 | $46,596,000 | $24,175,000 |
| Capital Stock | $2,000 | $1,000 | $12,000 |
| Common Stock | $2,000 | $1,000 | $12,000 |
| Preferred Stock | $0 | $0 | $0 |
| Current Accrued Expenses | $1,031,000 | $285,000 | $48,000 |
| Net PPE | $21,000 | $16,000 | $0 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|
| Free Cash Flow | $-8,272,000 | $-6,667,000 | $-1,854,000 |
Operating Activities
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|
| Operating Cash Flow | $-8,258,000 | $-6,648,000 | $-1,854,000 |
| Cash Flow From Continuing Operating Activities | $-8,258,000 | $-6,648,000 | $-1,854,000 |
| Operating Gains Losses | - | $8,000,000 | - |
Investing Activities
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|
| Capital Expenditure | $-14,000 | $-19,000 | - |
| Investing Cash Flow | $-14,000 | $-19,000 | $0 |
| Cash Flow From Continuing Investing Activities | $-14,000 | $-19,000 | $0 |
Financing Activities
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|
| Issuance Of Capital Stock | $10,027,000 | $13,706,000 | $675,000 |
| Financing Cash Flow | $8,800,000 | $14,410,000 | $675,000 |
| Cash Flow From Continuing Financing Activities | $8,800,000 | $14,410,000 | $675,000 |
| Net Other Financing Charges | $-1,228,000 | $-1,296,000 | - |
| Net Common Stock Issuance | $10,027,000 | $13,706,000 | $675,000 |
| Common Stock Issuance | $10,027,000 | $13,706,000 | $675,000 |
Other
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|
| Issuance Of Debt | $0 | $2,000,000 | $0 |
| End Cash Position | $9,136,000 | $8,608,000 | $865,000 |
| Beginning Cash Position | $8,608,000 | $865,000 | $2,044,000 |
| Changes In Cash | $528,000 | $7,743,000 | $-1,179,000 |
| Proceeds From Stock Option Exercised | $1,000 | $0 | - |
| Net Issuance Payments Of Debt | $0 | $2,000,000 | $0 |
| Net Long Term Debt Issuance | $0 | $2,000,000 | $0 |
| Long Term Debt Issuance | $0 | $2,000,000 | $0 |
| Net PPE Purchase And Sale | $-14,000 | $-19,000 | $0 |
| Purchase Of PPE | $-14,000 | $-19,000 | $0 |
| Change In Working Capital | $1,240,000 | $79,000 | $136,000 |
| Change In Other Current Assets | $310,000 | $-478,000 | $9,000 |
| Change In Payables And Accrued Expense | $930,000 | $557,000 | $127,000 |
| Change In Accrued Expense | $746,000 | $237,000 | $46,000 |
| Change In Payable | $184,000 | $320,000 | $81,000 |
| Change In Account Payable | $184,000 | $320,000 | $81,000 |
| Other Non Cash Items | $101,000 | - | - |
| Stock Based Compensation | $1,628,000 | $618,000 | $0 |
| Depreciation Amortization Depletion | $183,000 | $81,000 | $0 |
| Depreciation And Amortization | $183,000 | $81,000 | $0 |
| Net Income From Continuing Operations | $-11,410,000 | $-15,426,000 | $-1,990,000 |
| Gain Loss On Investment Securities | - | $8,000,000 | - |